Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

α-1 antitrypsin and chronic fatigue syndrome: a case study from pathophysiology to clinical practice.

Alegre J, Camprubí S, García-Quintana A.

Pain Manag. 2013 Mar;3(2):119-22. doi: 10.2217/pmt.12.84.

PMID:
24645995
[PubMed]
2.

Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.

Jonigk D, Al-Omari M, Maegel L, Müller M, Izykowski N, Hong J, Hong K, Kim SH, Dorsch M, Mahadeva R, Laenger F, Kreipe H, Braun A, Shahaf G, Lewis EC, Welte T, Dinarello CA, Janciauskiene S.

Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):15007-12. doi: 10.1073/pnas.1309648110. Epub 2013 Aug 23.

PMID:
23975926
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin.

Maes M, Twisk FN, Kubera M, Ringel K.

J Affect Disord. 2012 Feb;136(3):933-9. doi: 10.1016/j.jad.2011.09.004. Epub 2011 Oct 4.

PMID:
21975140
[PubMed - indexed for MEDLINE]
4.

Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series.

Fluge Ø, Mella O.

BMC Neurol. 2009 Jul 1;9:28. doi: 10.1186/1471-2377-9-28.

PMID:
19566965
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Information processing efficiency in chronic fatigue syndrome and multiple sclerosis.

DeLuca J, Johnson SK, Natelson BH.

Arch Neurol. 1993 Mar;50(3):301-4.

PMID:
8442710
[PubMed - indexed for MEDLINE]
6.

Expanding the clinical indications for α(1)-antitrypsin therapy.

Lewis EC.

Mol Med. 2012 Sep 7;18:957-70. doi: 10.2119/molmed.2011.00196. Review.

PMID:
22634722
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation.

Maes M, Ringel K, Kubera M, Anderson G, Morris G, Galecki P, Geffard M.

J Affect Disord. 2013 Sep 5;150(2):223-30. doi: 10.1016/j.jad.2013.03.029. Epub 2013 May 10.

PMID:
23664637
[PubMed - indexed for MEDLINE]
8.

Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.

Piitulainen E, Bernspång E, Björkman S, Berntorp E.

Eur J Clin Pharmacol. 2003 Jun;59(2):151-6. Epub 2003 May 1.

PMID:
12728289
[PubMed - indexed for MEDLINE]
9.
10.

Alpha-1 antitrypsin augmentation therapy.

Wewers MD, Crystal RG.

COPD. 2013 Mar;10 Suppl 1:64-7. doi: 10.3109/15412555.2013.764402. Review.

PMID:
23527997
[PubMed - indexed for MEDLINE]
11.

Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin.

Stoller JK, Rouhani F, Brantly M, Shahin S, Dweik RA, Stocks JM, Clausen J, Campbell E, Norton F.

Chest. 2002 Jul;122(1):66-74.

PMID:
12114340
[PubMed - indexed for MEDLINE]
12.

Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome.

Gaab J, Rohleder N, Heitz V, Engert V, Schad T, Schürmeyer TH, Ehlert U.

Psychoneuroendocrinology. 2005 Feb;30(2):188-98.

PMID:
15471616
[PubMed - indexed for MEDLINE]
13.

A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.

Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT, Goldstein J, O'Neill W.

Drugs Today (Barc). 2002 Aug;38(8):549-61. Review.

PMID:
12582420
[PubMed - indexed for MEDLINE]
14.

A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome.

Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, Lurie N.

Am J Med. 1990 Nov;89(5):554-60.

PMID:
2239975
[PubMed - indexed for MEDLINE]
15.

Chronic fatigue syndrome: lack of association between pain-related fear of movement and exercise capacity and disability.

Nijs J, Vanherberghen K, Duquet W, De Meirleir K.

Phys Ther. 2004 Aug;84(8):696-705.

PMID:
15283620
[PubMed - indexed for MEDLINE]
Free Article
16.

New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.

Gross B, Grebe M, Wencker M, Stoller JK, Bjursten LM, Janciauskiene S.

Dermatology. 2009;218(4):370-5. doi: 10.1159/000202982. Epub 2009 Feb 16.

PMID:
19218787
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

EEG biofeedback as a treatment for chronic fatigue syndrome: a controlled case report.

James LC, Folen RA.

Behav Med. 1996 Summer;22(2):77-81.

PMID:
8879459
[PubMed - indexed for MEDLINE]
18.

Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy.

Zamora NP, Pla RV, Del Rio PG, Margaleff RJ, Frias FR, Ronsano JB.

Ann Pharmacother. 2008 May;42(5):640-6. doi: 10.1345/aph.1K505. Epub 2008 Apr 15. Erratum in: Ann Pharmacother. 2008 Jun;42(6):905. Ronsano, Jose Bruono Montoro [corrected Ronsano, Jose Bruno Montoro].

PMID:
18413692
[PubMed - indexed for MEDLINE]
19.

alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia.

Blanco LE, de Serres FJ, Fernańdez-Bustillo E, Kassam DA, Arbesú D, Rodríguez C, Torre JC.

Med Hypotheses. 2005;64(4):759-69.

PMID:
15694694
[PubMed - indexed for MEDLINE]
20.

Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?

Abboud RT, Ford GT, Chapman KR.

Treat Respir Med. 2005;4(1):1-8. Review.

PMID:
15725045
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk